Paul Tudor Jones Kodiak Sciences Inc. Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$4.3 - $9.48 $68,916 - $151,935	16,027 New	16,027 $110,000
Q2 2022 Aug 15, 2022	SELL	$5.04 - $9.48 $52,395 - $98,554	-10,396 Reduced 48.18%	11,181 $85,000
Q1 2022 May 16, 2022	BUY	$7.09 - $89.45 $130,519 - $1.65 Million	18,409 Added 581.09%	21,577 $167,000
Q4 2021 Feb 14, 2022	BUY	$80.85 - $128.49 $256,132 - $407,056	3,168 New	3,168 $269,000
Q3 2021 Nov 15, 2021	SELL	$81.97 - $106.94 $705,843 - $920,860	-8,611 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$77.2 - $126.54 $183,658 - $301,038	2,379 Added 38.17%	8,611 $801,000
Q1 2021 May 17, 2021	BUY	$110.45 - $164.47 $531,927 - $792,087	4,816 Added 340.11%	6,232 $707,000
Q4 2020 Feb 16, 2021	BUY	$60.78 - $154.03 $86,064 - $218,106	1,416 New	1,416 $208,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.